Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 64.82 CNY -4.11% Market Closed
Market Cap: 48.1B CNY
Have any thoughts about
Hangzhou Tigermed Consulting Co Ltd?
Write Note

Hangzhou Tigermed Consulting Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hangzhou Tigermed Consulting Co Ltd
Total Equity Peer Comparison

Comparables:
603259
300759
2269
1548
W
2268

Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Equity
ÂĄ20.8B
CAGR 3-Years
7%
CAGR 5-Years
41%
CAGR 10-Years
39%
WuXi AppTec Co Ltd
SSE:603259
Total Equity
ÂĄ54.7B
CAGR 3-Years
14%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Equity
ÂĄ13B
CAGR 3-Years
12%
CAGR 5-Years
36%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Equity
ÂĄ40.7B
CAGR 3-Years
7%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Genscript Biotech Corp
HKEX:1548
Total Equity
$1.4B
CAGR 3-Years
11%
CAGR 5-Years
25%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Total Equity
ÂĄ5.5B
CAGR 3-Years
144%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Hangzhou Tigermed Consulting Co Ltd's Total Equity?
Total Equity
20.8B CNY

Based on the financial report for Jun 30, 2024, Hangzhou Tigermed Consulting Co Ltd's Total Equity amounts to 20.8B CNY.

What is Hangzhou Tigermed Consulting Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
39%

Over the last year, the Total Equity growth was 1%. The average annual Total Equity growth rates for Hangzhou Tigermed Consulting Co Ltd have been 7% over the past three years , 41% over the past five years , and 39% over the past ten years .

Back to Top